Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study


Immix Biopharma Inc IMMX announced preclinical data of its lead program, IMX-110.

  • The data showed that IMX-110 produced a 50% response rate in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study.  
  • The responses were assessed by RECIST 1.1 criteria applied to mice, with progression assessed after one treatment cycle.
  • The FDA has approved orphan drug designation for IMX-110 for soft tissue sarcoma. The FDA has already approved rare pediatric disease designation to IMX-110 for pediatric cancer, rhabdomyosarcoma.
  • ImmixBio recently shared IMX-110 clinical data across multiple STS subtypes in several heavily pretreated patients demonstrating median progression-free survival (PFS) of 4 months.
  • Zero drug-related severe adverse events and dose interruptions due to toxicity were observed. 
  • Price Action: IMMX shares are up 31.7% at $7.15 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralBriefsPreclinical Phasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!